Related Experiment Video
Updated: May 24, 2026

Technique of Porcine Liver Procurement and Orthotopic Transplantation using an Active Porto-Caval Shunt
Published on: May 7, 2015
Liver cancer: effects, safety, and cost-effectiveness of controlled-release oxycodone for pain control after TACE
Bo Zhou1, Jianhua Wang, Zhiping Yan
1Department of Interventional Radiology, Fudan University, Shanghai Medical College, Zhongshan Hospital, 180 Fenglin Rd, Shanghai 200032, People's Republic of China.
Purpose:
To evaluate the analgesic effect, safety, and cost-effectiveness of controlled-release oxycodone (CRO) to control postoperative pain in patients with liver cancer who are undergoing transarterial chemoembolization.
Materials And Methods:
This randomized, double-blind, placebo-controlled, prospective clinical study received institutional review board approval. After written informed consent was obtained, 210 patients with liver cancer were randomized into three groups of 70 patients. Group 1 received 20 mg of CRO, group 2 received 10 mg of CRO, and group 3 received a placebo at 1 hour before transarterial chemoembolization (T(0)) and 12 (T(12)) and 24 (T(24)) hours after T(0). Pain intensity on a numeric rating scale, percentage of patients with each degree of pain, quality of life, adverse reactions, analgesic costs, and hospital stays were evaluated and compared among the three groups.
Results:
Numeric rating scale scores for pain intensity in group 1 and group 2 were significantly lower than those in group 3 at T(0-12) (P < .001); T(12-24) (P < .001); and T(24-48) (P < .001). When group 1 with group 2 were compared, numeric rating scale scores were significantly lower in group 1 than in group 2 during the period of T(0-12) (P < .001) but were not significantly different at T(12-24) (P = .68) and T(24-48) (P = .10). Analgesic cost and hospital stay were significantly lower in treated groups than in the placebo group. No significant difference was observed in quality of life and adverse events between the treated groups and the placebo group.
Conclusion:
CRO is effective, safe, and cost-effective in the control of postoperative pain after transarterial chemoembolization for patients with inoperable liver cancer.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
